Calibr, a nonprofit affiliated with Scripps Research, announced a collaboration with pharmaceutical AbbVie built on developing therapies, primarily for cancer, including solid tumors.

Deal terms were not disclosed, but it’s subject to the Hart-Scott-Rodino Antitrust Improvements Act, which covers certain transactions of at least $84.4 million.

Under the agreement, AbbVie will pay Calibr an upfront fee, and in exchange gain exclusive access to Calibr’s platform, which harnesses a cancer patient’s immune system to attack cancer cells. The term is up to four years.

Calibr’s platform revolves around Chimeric Antigen Receptor T-cell (CAR-T) therapies.

At the center of the multi-faceted deal is that the companies will share preclinical development responsibilities, and AbbVie will shoulder clinical development and commercialization. Calibr is eligible for milestone payments and royalties.

The focus of the collaboration is solid tumors, but AbbVie could identify other cancer targets.